Tiantan Bio: Subsidiary Chengdu Rongsheng received Drug GMP Compliance Inspection Notice

Tiantan Biology announced that its subsidiary Chengdu Rongsheng has received a "Drug GMP Compliance Inspection Notification" from the Sichuan Provincial Drug Administration, with the inspection scope covering the production workshop and related areas of blood products. The blood product production workshop of Chengdu Rongsheng meets the national GMP requirements, and once the relevant registration certificate and production license are obtained, production of the product can begin. The product has completed Phase III clinical trials and a marketing license application has been submitted. However, future production may be affected by various factors and carries uncertainty.